EZH2 and myelodysplastic syndrome: Studies have shown that mutations in the spliceosome and the methylation pathways with additional mutations in RUNX1, BCOR, EZH2, CBL, CUX1, and IDH1/IDH2 are highly specific for MDS in the right clinical setting [33].